Arcus Biosciences discloses preliminary cash estimate in 8-K filing

Arcus Biosciences, Inc. filed a Form 8-K dated October 21, 2026, disclosing a preliminary estimate of its cash position for the third quarter of 2026. The filing does not include any disclosures on trial starts, clinical readouts, or regulatory milestones.

Based on preliminary estimates and information available as of October 21, 2026, the company estimated it had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.¹

The company cautioned that this figure is not final. The estimate is preliminary and subject to completion of the company's financial closing procedures, including management's reviews, and may vary from its actual financial position as of September 30, 2026.¹ The company also noted that the estimate is not a comprehensive statement of its financial results or condition as of that date.¹

Arcus stated that the figures were prepared internally. The preliminary cash balance included in the filing was prepared by, and is the responsibility of, the company's management.¹ Ernst & Young LLP, the company's independent registered public accounting firm, has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to the preliminary financial data, and does not express an opinion or other assurance on it.¹

The company further noted that the preliminary estimate should not be viewed as a substitute for financial statements prepared under U.S. generally accepted accounting principles and is not necessarily indicative of the balance to be achieved in any future period, with additional information required for a more complete understanding of its financial position and results of operations as of September 30, 2026.¹

The filing was signed by Terry Rosen, Ph.D., Chief Executive Officer of Arcus Biosciences, on October 21, 2026.